##### Table of Contents



SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
 FORM 10-Q þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For The Quarterly Period Ended March 31, 2005 OR £
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 Commission File Number 0-26825 NORTHWEST BIOTHERAPEUTICS, INC.  DELAWARE
(State or Other Jurisdiction of
Incorporation or Organization)
    
    94-3306718
(I.R.S. Employer Identification
No.)
 Canyon Park Building 8, 22322 20th Avenue S.E., Suite 150, Bothell, Wa. 98021
(Address of Principal Executive Offices, Including Zip Code) (425) 608-3000
(Registrants Telephone Number, Including Area Code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No £ Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule
12b-2 of the Exchange Act). Yes £ No þ As of May 13, 2005, the registrant had outstanding 19,078,048 shares of common stock, $0.001
par value.




---



TABLE OF CONTENTS NORTHWEST BIOTHERAPEUTICS, INC. TABLE OF CONTENTS PagePART I  FINANCIAL INFORMATIONItem 1. Financial Statements (unaudited)Condensed Balance Sheets
    
    
    3Condensed Statements of Operations
    
    
    4Condensed Statements of Cash Flows
    
    
    5Notes to Condensed Financial Statements
    
    
    7Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    12Item 3. Quantitative and Qualitative Disclosures About Market Risk
    
    
    23Item 4. Controls and Procedures
    
    
    23PART II  OTHER INFORMATIONItem 1. Legal Proceedings
    
    
    24Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    24Item 3. Defaults Upon Senior Securities
    
    
    25Item 4. Submission of Matters to a Vote of Security Holders
    
    
    25Item 5. Other Information
    
    
    25Item 6. Exhibits
    
    
    25SIGNATURES
    
    
    27INDEX TO EXHIBITS
    
    
    28EXHIBIT 31.1EXHIBIT 31.2EXHIBIT 32.1EXHIBIT 32.2
  2




---



##### Table of Contents



Part I  Financial Information NORTHWEST BIOTHERAPEUTICS, INC .
(A Development Stage Company) 
 Balance Sheets
(in thousands)
(Unaudited) December 31,
    
    
    March 31,2004
    
    
    2005AssetsCurrent assets:Cash
    
    $
    248
    
    
    $
    52Accounts receivable
    
    
    11
    
    
    
    44Accounts receivable, related party
    
    
    
    
    
    
    58Prepaid expenses and other current assets
    
    
    151
    
    
    
    84Total current assets
    
    
    410
    
    
    
    238Property and equipment:Leasehold improvements
    
    
    69
    
    
    
    69Laboratory equipment
    
    
    139
    
    
    
    139Office furniture and other equipment
    
    
    104
    
    
    
    104312
    
    
    
    312Less accumulated depreciation and amortization
    
    
    (194
    )
    
    
    (218
    )Property and equipment, net
    
    
    118
    
    
    
    94Restricted cash
    
    
    30
    
    
    
    30Total assets
    
    $
    558
    
    
    $
    362Liabilities And Stockholders EquityCurrent liabilities:Note payable to related parties, net of discount
    
    $
    3,226
    
    
    $
    3,978Current portion of capital lease obligations
    
    
    38
    
    
    
    32Accounts payable
    
    
    1,453
    
    
    
    1,816Accrued expenses
    
    
    201
    
    
    
    120Accrued expense, tax liability
    
    
    494
    
    
    
    503Accrued expense, related party
    
    
    316
    
    
    
    366Deferred grant revenue
    
    
    35
    
    
    
    Total current liabilities
    
    
    5,763
    
    
    
    6,815Long-term liabilities:Capital lease obligations, net of current portion
    
    
    12
    
    
    
    7Total liabilities
    
    
    5,775
    
    
    
    6,822Stockholders equity:Preferred stock, $0.001 par value; 100,000,000
shares authorized and 32,500,000
shares issued and outstanding at March 31, 2005.
    
    
    
    
    
    
    33Common stock, $0.001 par value; 300,000,000
shares authorized and 19,028,779 and 19,063,778
shares issued and outstanding at December 31, 2004
and March 31, 2005, respectively
    
    
    19
    
    
    
    19Additional paid-in capital
    
    
    67,524
    
    
    
    68,770Deferred compensation
    
    
    (7
    )
    
    
    (3
    )Deficit accumulated during the development stage
    
    
    (72,753
    )
    
    
    (75,279
    )Total stockholders equity
    
    
    (5,217
    )
    
    
    (6,460
    )Total liabilities and stockholders equity
    
    $
    558
    
    
    $
    362
 See accompanying notes to condensed financial statements. 3




---



##### Table of Contents



NORTHWEST BIOTHERAPEUTICS, INC.
(A Development Stage Company) 
 Statements of Operations
(in thousands, except per share data)
(Unaudited) Period fromMarch 18, 1996Three Months Ended
    
    
    (Inception) toMarch 31,
    
    
    March 31,2004
    
    
    2005
    
    
    2005Revenues:Research material sales
    
    $
    24
    
    
    $
    11
    
    
    $
    423Contract research and development
from related parties
    
    
    
    
    
    
    
    
    
    
    1,128Research grants
    
    
    103
    
    
    
    76
    
    
    
    1,051Total revenues
    
    
    127
    
    
    
    87
    
    
    
    2,602Operating expenses:Cost of research material sales
    
    
    25
    
    
    
    2
    
    
    
    372Research and development
    
    
    229
    
    
    
    1,315
    
    
    
    28,910General and administrative
    
    
    557
    
    
    
    464
    
    
    
    29,153Depreciation and amortization
    
    
    37
    
    
    
    24
    
    
    
    2,227Loss on facility sublease and lease
cancellation
    
    
    
    
    
    
    
    
    
    
    895Asset impairment loss
    
    
    
    
    
    
    
    
    
    
    2,066Total operating expenses
    
    
    848
    
    
    
    1,805
    
    
    
    63,623Loss from operations
    
    
    (721
    )
    
    
    (1,718
    )
    
    
    (61,021
    )Other income (expense):Warrant valuation
    
    
    
    
    
    
    
    
    
    
    (368
    )Gain on sale of royalty rights
    
    
    
    
    
    
    
    
    
    
    3,656Interest expense
    
    
    (107
    )
    
    
    (809
    )
    
    
    (10,429
    )Interest income
    
    
    
    
    
    
    1
    
    
    
    732Net loss
    
    
    (828
    )
    
    
    (2,526
    )
    
    
    (67,430
    )Accretion of Series A preferred stock mandatory
redemption obligation
    
    
    
    
    
    
    
    
    
    
    (1,872
    )Series A preferred stock redemption fee
    
    
    
    
    
    
    
    
    
    
    (1,700
    )Beneficial conversion feature of Series D
preferred stock
    
    
    
    
    
    
    
    
    
    
    (4,274
    )Net loss applicable to common stockholders
    
    $
    (828
    )
    
    $
    (2,526
    )
    
    $
    (75,276
    )Net loss per share applicable to common
stockholders  basic and diluted
    
    $
    (0.04
    )
    
    $
    (0.13
    )Weighted average shares used in computing basic
and diluted loss per share (in thousands)
    
    
    19,025
    
    
    
    19,035
 See accompanying notes to condensed financial statements. 4




---



##### Table of Contents



NORTHWEST BIOTHERAPEUTICS, INC .
(A Development Stage Company) 
 Condensed Statement of Cash Flows
(in thousands)
(Unaudited) Period fromThree Months Ended
    
    
    March 18, 1996March 31,
    
    
    (Inception) to2004
    
    
    2005
    
    
    March 31, 2005Cash Flows from Operating Activities:Net Loss
    
    $
    (828
    )
    
    $
    (2,526
    )
    
    $
    (67,430
    )Reconciliation of net loss to net cash used in operating activities:Depreciation and amortization
    
    
    37
    
    
    
    24
    

    
    
    2,226Amortization of deferred financing costs
    
    
    
    
    
    
    
    
    
    
    320Amortization debt discount
    
    
    96
    
    
    
    695
    
    
    
    8,045Accrued interest converted to preferred stock
    
    
    
    
    
    
    
    
    
    
    260Accreted interest on convertible promissory note
    
    
    7
    
    
    
    112
    
    
    
    306Stock-based compensation costs
    
    
    20
    
    
    
    4
    
    
    
    1,087Loss (gain) on sale and disposal of property and equipment
    
    
    
    
    
    
    
    
    
    
    475Gain on sale of intellectual property and royalty rights
    
    
    
    
    
    
    
    
    
    
    (3,656
    )Gain on sale of property and equipment
    
    
    (1
    )
    
    
    (81
    )
    
    
    (217
    )Warrant valuation
    
    
    
    
    
    
    
    
    
    
    368Asset impairment loss
    
    
    
    
    
    
    
    
    
    
    2,066Loss on facility sublease
    
    
    
    
    
    
    
    
    
    
    895Increase (decrease) in cash resulting from changes in assets and liabilities:Accounts receivable
    
    
    (38
    )
    
    
    (86
    )
    
    
    (97
    )Prepaid expenses and other current assets
    
    
    (7
    )
    
    
    63
    
    
    
    378Accounts payable and accrued expenses
    
    
    252
    
    
    
    341
    
    
    
    3,203Accrued loss on sublease
    
    
    
    
    
    
    
    
    
    
    (266
    )Deferred grant revenue
    
    
    207
    
    
    
    (35
    )
    
    
    Deferred rent
    
    
    (5
    )
    
    
    
    
    
    
    410Net Cash used in Operating Activities
    
    
    (260
    )
    
    
    (1,489
    )
    
    
    (51,627
    )Cash Flows from Investing Activities:Purchase of property and equipment, net
    
    
    
    
    
    
    
    
    
    
    (4,537
    )Proceeds from sale of property and equipment
    
    
    1
    
    
    
    81
    
    
    
    217Proceeds from sale of intellectual property
    
    
    
    
    
    
    
    
    
    
    1,816Proceeds from sale of marketable securities
    
    
    
    
    
    
    
    
    
    
    2,000Transfer of restricted cash
    
    
    75
    
    
    
    
    
    
    
    (1,034
    )Net Cash provided by (used in) Investing Activities
    
    
    76
    
    
    
    81
    
    
    
    (1,538
    )Cash Flows from Financing Activities:Proceeds from issuance of note payable to stockholder
    
    
    
    
    
    
    
    
    
    
    1,650Repayment of note payable to stockholder
    
    
    
    
    
    
    
    
    
    
    (1,650
    )Proceeds from issuance of convertible promissory note and warrants, net of issuance costs
    
    
    100
    
    
    
    
    
    
    
    9,749Borrowing under line of credit, Northwest Hospital
    
    
    
    
    
    
    
    
    
    
    2,834Repayment of line of credit, Northwest Hospital
    
    
    
    
    
    
    
    
    
    
    (2,834
    )Repayment of convertible promissory note
    
    
    
    
    
    
    (55
    )
    
    
    (107
    )Payment on capital lease obligations
    
    
    (11
    )
    
    
    (11
    )
    
    
    (284
    )Payments on note payable
    
    
    
    
    
    
    
    
    
    
    (420
    )Proceeds from issuance Series A cumulative preferred stock, net
    
    
    
    
    
    
    1,276
    
    
    
    28,708Proceeds from exercise of stock options and warrants
    
    
    
    
    
    
    2
    
    
    
    222Proceeds from issuance common stock, net
    
    
    
    
    
    
    
    
    
    
    17,369Mandatorily redeemable Series A preferred stock redemption fee
    
    
    
    
    
    
    
    
    
    
    (1,700
    )Deferred financing costs
    
    
    
    
    
    
    
    
    
    
    (320
    )Net Cash provided by Financing Activities
    
    
    89
    
    
    
    1,212
    
    
    
    53,217Net increase (decrease) in cash and cash equivalents
    
    
    (95
    )
    
    
    (196
    )
    
    
    52Cash and cash equivalents at beginning of period
    
    
    255
    
    
    
    248
    
    
    
    Cash and cash equivalents at end of period
    
    $
    160
    
    
    $
    52
    
    
    $
    52Supplemental disclosure of cash flow information 
Cash paid during the period for interest
    
    $
    3
    
    
    $
    2
    
    
    $
    1,391Supplemental schedule of non-cash financing activities
Equipment acquired through capital leases
    
    
    
    
    
    
    
    
    
    
    285Common stock warrant liability
    
    
    
    
    
    
    
    
    
    
    4,714Accretion of mandatorily redeemable Series A preferred stock redemption obligation
    
    
    
    
    
    
    
    
    
    
    1,872Beneficial conversion feature of convertible promissory notes
    
    
    
    
    
    
    
    
    
    
    3,793Conversion of convertible promissory notes and accrued interest to Series D preferred stock
    
    
    
    
    
    
    
    
    
    
    5,324Issuance of Series C preferred stock warrants in connection with lease agreement
    
    
    
    
    
    
    
    
    
    
    43Issuance of common stock for license rights
    
    
    
    
    
    
    
    
    
    
    4
 5




---



##### Table of Contents



Period fromThree Months Ended
    
    
    March 18, 1996March 31,
    
    
    (Inception) to2004
    
    
    2005
    
    
    March 31, 2005Issuance of common stock and warrants to Medarex
    
    
    
    
    
    
    
    
    
    
    840Issuance of common stock to landlord
    
    
    
    
    
    
    
    
    
    
    35Deferred compensation on issuance of stock options and restricted stock grants
    
    
    
    
    
    
    4
    
    
    
    756Cancellation of options and restricted stock
    
    
    
    
    
    
    
    
    
    
    849Stock subscription receivable
    
    
    
    
    
    
    
    
    
    
    480Financing of prepaid insurance through note payable
    
    
    
    
    
    
    
    
    
    
    420
 See accompanying notes to condensed financial statements. 6




---



##### Table of Contents



NORTHWEST BIOTHERAPEUTICS, INC .
(A Development Stage Company) 
 Notes to Condensed
Financial Statements
(unaudited) 1. Basis of Presentation The accompanying unaudited financial statements for Northwest Biotherapeutics, Inc. have been
prepared in accordance with accounting principles generally accepted in the United States for
interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes required by accounting
principles generally accepted in the United States for complete financial statements. In the
opinion of management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the three-month period
ended March 31, 2005 are not necessarily indicative of the results that may be expected for the
year ending December 31, 2005. For further information, refer to the financial statements and footnotes thereto included in
our Annual Report on Form 10-K for the year ended December 31, 2004, as filed with the Securities
and Exchange Commission. The auditors report on our financial statements for the fiscal year ended December 31, 2004
states that because of recurring operating losses, a working capital deficit, and a deficit
accumulated during the development stage, there is substantial doubt about our ability to continue
as a going concern. A going concern opinion indicates that the financial statements have been
prepared assuming we will continue as a going concern and do not include any adjustments to reflect
the possible future effects on the recoverability and classification of assets or the amounts and
classification of liabilities that may result from the outcome of this uncertainty. Stock-Based Compensation We account for our stock option plans for employees in accordance with the provisions of
Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and
related interpretations. As such, compensation expense related to employee stock options is
recorded if, on the date of grant, the fair value of the underlying stock exceeds the exercise
price. We apply the disclosure-only requirements of SFAS No. 123, Accounting for Stock-Based
Compensation, which allows entities to continue to apply the provisions of APB Opinion No. 25 for
transactions with employees, and to provide pro-forma results of operations disclosures for
employee stock option grants as if the fair-value-based method of accounting in SFAS No. 123 had
been applied to those transactions. Stock compensation costs related to fixed employee awards with pro rata vesting are recognized
on a straight-line basis over the period of benefit, generally the vesting period of the options.
For options and warrants issued to non-employees, we recognize stock compensation costs utilizing
the fair value methodology prescribed in SFAS No. 123 over the related period of benefit. Had we recognized the compensation cost of employee stock options based on the fair value of
the options on the date of grant as prescribed by SFAS No. 123, the pro-forma net loss applicable
to common stockholders and related loss per share would have been adjusted to the pro-forma amounts
indicated below: Three months ended March 31,2004
    
    
    2005Net loss applicable to common stockholders as reportedAs reported
    
    $
    (828
    )
    
    
    (2,526
    )Add: Stock-based employee compensation expense
included in reported net loss, net
    
    
    20
    
    
    
    4Deduct: Stock-based employee compensation determined
under fair value based method for all awards
    
    
    (84
    )
    
    
    (24
    )Pro forma
    
    $
    (892
    )
    
    $
    (2,546
    )Net loss per share-basic and diluted:As reported
    
    $
    (0.04
    )
    
    $
    (0.13
    )Pro forma
    
    $
    (0.05
    )
    
    $
    (0.13
    )
 7




---



##### Table of Contents



There were no stock options granted during the three months ended March 31, 2004. The
per share weighted average fair value of stock options granted during the three months ended March
31, 2005 was $0.21. The weighted average fair values were determined on the date of grant using
the following weighted average assumptions: Three months ended March 31, 2005Risk-free interest rate
    
    
    2.17%Expected life
    
    
    5.0 yearsExpected volatility
    
    
    254.55%Dividend yield
    
    
    0.00
 2. Liquidity From February 2, 2004 to March 31, 2005, we have undergone a significant recapitalization pursuant to
which Toucan Capital Fund II, L.P., or Toucan Capital, has loaned us
$4.35 million. On January 26,
2005, we entered into a securities purchase agreement with Toucan Capital pursuant to which they
purchased 32.5 million shares of our newly designated series A preferred stock at a purchase price
of 0.04 per share, for a net purchase price of $1.276 million, net of issue related costs of
approximately $24,000. As
of March 31, 2005, we had cash of approximately $82,000.
We will have to seek additional funds from Toucan Capital, which
Toucan Capital is not
obligated to provide to us. Any additional financing with Toucan Capital or any other third party is likely to be dilutive
to stockholders, and any debt financing, if available, may include additional restrictive
covenants. If we are unable to obtain significant additional capital in the near-term, we may cease
operations at anytime. We do not believe that our assets would be sufficient to satisfy the claims
of all of our creditors in full. Therefore, if we were to pursue a liquidation it is highly
unlikely that any proceeds would be received by our stockholders. Our independent auditors have indicated in their report on our financial statements, included
in our December 31, 2004 annual report on Form 10-K, that there is substantial doubt about our
ability to continue as a going concern. We need to raise significant additional funding to continue
our operations, conduct research and development activities, pre-clinical studies and clinical
trials necessary to bring our product candidates to market. However, additional funding may not be
available on terms acceptable to us or at all. The alternative of issuing additional equity or
convertible debt securities also may not be available and, in any event, would result in additional
dilution to our stockholders. 3. Net Loss Per Share Applicable to Common Stockholders Basic and diluted net loss per share applicable to common stockholders has been computed using
the weighted-average number of shares of common stock outstanding during the period, less, for the
three months ended March 31, 2005, options to purchase 784,000 shares of common stock and warrants
to purchase 117 million shares of common and preferred stock as such securities were antidilutive.
Options to purchase 1.2 million shares of common stock and warrants to purchase 5 million shares of
common and preferred stock were excluded from the calculation of diluted net loss per share for the
three months ended March 31, 2004 as such securities were antidilutive. 4. Notes Payable to Related Parties Management Loans On November 13, 2003, we borrowed an aggregate of $335,000 from members of our management
enabling us to continue operating into the first quarter of 2004. Net of repayments, the loan
liability remaining at March 31, 2005 is $235,000, as more fully described in the following table: 8




---



##### Table of Contents



Name
    
    Title
    
    PrincipalAlton L. Boynton, Ph.D.
    
    President, Chief Scientific Officer, Chief Operating Officer and Secretary
    
    $
    183,000Marnix Bosch, Ph.D.
    
    Vice President of Vaccine Research and Development
    
    
    41,000Larry L. Richards
    
    Controller (Principal Financial and Accounting Officer)
    
    
    11,000Total
    
    $
    235,000
 The notes initially had a 12-month term, accrue interest at an annual rate equal to
the prime rate plus 2% and were initially secured by substantially all of our assets not otherwise
collateralized. The aggregate principal amount of the five notes was $335,000 of which $50,000,
including interest of $1,674, was repaid on June 1, 2004 and $50,000, including interest of $4,479,
was repaid on February 24, 2005. In connection with the April 26, 2004 recapitalization agreement
with Toucan Capital, holders of notes representing 70% of the principal amount of the notes agreed
to an amendment to their notes to set the conversion price of the amended notes at $0.10 per share
and change the maturity date to November 12, 2004 in the event the Company raises at least $15
million in a financing prior to that time or May 12, 2005 if the Company has not completed a $15
million financing by May 12, 2005. The maturity date for these notes was subsequently changed to
July 12, 2005. As part of the November 13, 2003 loan, the investors received warrants initially exercisable
to acquire an aggregate of 3.7 million shares of the Companys common stock, expiring November 2008
subject to certain antidilution adjustments, at an exercise price to be determined as follows: (i)
in the event that the Company completes an offering of its common stock generating gross proceeds
of at least $1 million, then the price per share paid by investors in that offering; or (ii) if the
Company does not complete such an offering, then $0.18, which was the closing price of its common
stock on the date of the financing. In connection with the April 26, 2004 recapitalization
agreement, certain members of management who hold warrants agreed to an amendment to their
warrants. The amendment applies to all warrants issued in the November 13, 2003 financing. The
purpose of the amendment was to remove the anti-dilution provisions and set the warrant exercise
price at the lesser of (i) $0.10 per share or (ii) a 35% discount to the average closing price
during the twenty trading days prior to the first closing of the sale by the Company of convertible
preferred stock as contemplated by the recapitalization agreement but not less than $0.04 per
share. Proceeds from the offering were allocated between the Notes and Warrants on a relative fair
value basis. The value allocated to the warrants on the date of the grant was approximately
$221,000. The fair value of the warrants was determined using the Black-Scholes option pricing
model with the following assumptions: expected dividend yield of 0%, risk-free interest rate of
3.36%, volatility of 194%, and a contractual life of 5-years. The value of the warrants was
recorded as a deferred debt discount against the $335,000 proceeds of the Note. In addition, a
beneficial conversion feature related to the Notes was determined to be approximately $221,000 but
is capped at the remaining value originally allocated to the Notes of approximately $114,000. As a
result, the total discount on the Notes equalled the face value of $335,000 which was fully
amortized by December 31, 2004. Toucan Capital Loans On April 26, 2004 we entered into a recapitalization agreement with Toucan Capital which
contemplates the possible recapitalization of our company. At Toucan Capitals option, and if
successfully implemented, the recapitalization could provide us with up to $40 million through the
issuance of new securities to Toucan Capital and a syndicate of other investors. Following the
recapitalization, Toucan Capital and the investor syndicate would potentially own, on a combined
basis, over 90% of our outstanding capital stock. As part of our recapitalization plan we
borrowed $4.35 million from Toucan Capital, from February 2, 2004 through March 31, 2005, comprised
of the following transactions: 9




---



##### Table of Contents



Loan Date
    
    Principal
    
    
    Due Date
    
    
    Accrued Interest (1)
    
    
    Convertible Shares
    
    
    Shares Warrant(In thousands)
    
    
    
    
    
    (In thousands)
    
    (In thousands)
    
    (In thousands) (2)(3)02/02/04 (6)
    
    $
    50
    
    
    
    06/26/05
    
    
    $
    6
    
    
    
    1,395
    
    
    
    3,000
    (4)03/01/04 (6)
    
    
    50
    
    
    
    06/26/05
    
    
    
    5
    
    
    
    1,385
    
    
    
    3,000
    (4)04/26/04 (6)
    
    
    500
    
    
    
    06/26/05
    
    
    
    46
    
    
    
    13,661
    
    
    
    30,000
    (4)06/11/04
    
    
    500
    
    
    
    06/11/05
    
    
    
    40
    
    
    
    13,503
    
    
    
    30,000
    (4)07/30/04
    
    
    2,000
    
    
    
    07/30/05
    
    
    
    134
    
    
    
    53,342
    
    
    
    20,000
    (5)10/22/04
    
    
    500
    
    
    
    10/22/05
    
    
    
    22
    
    
    
    13,047
    
    
    
    5,000
    (5)11/10/04
    
    
    500
    
    
    
    11/10/05
    
    
    
    19
    
    
    
    12,983
    
    
    
    5,000
    (5)12/27/04
    
    
    250
    
    
    
    12/27/05
    
    
    
    6
    
    
    
    6,411
    
    
    
    2,500
    (5)Total
    
    $
    4,350
    
    
    
    
    
    
    $
    278
    
    
    
    115,727
    
    
    
    98,500
  (1)
    As of March 31, 2005. Interest accrues at 10% per annum based on
a 365-day basis compounded annually from their respective
original issuance dates.(2)
    The warrant shares are exercisable for shares of convertible
preferred stock if the convertible preferred stock is approved
and authorized and other investors have purchased in cash a
minimum of $15 million of such convertible preferred stock, on
the terms and conditions set forth in the recapitalization
agreement. However, if, for any reason, such convertible
preferred stock is not approved or authorized and/or if other
investors have not purchased in cash a minimum of $15 million of
such convertible preferred stock, on the terms and conditions set
forth in the recapitalization agreement, these warrants shall be
exercisable for any equity security and/or debt security and/or
any combination thereof.(3)
    Exercise period is 7-years from the issuance date of the
convertible note except for the February 2 and March 1, 2004
warrants which have an April 26 exercise date.(4)
    Per share exercise price is $0.01(5)
    Per share exercise price is $0.04(6)
    The notes issued February 2, March 1, and April 26, 2004 to Toucan Capital were each
amended subsequently to change their respective maturity dates to June 26, 2005. The notes are secured by a first priority senior security interest in all of our assets. 5. Unregistered Sales of Equity Securities Toucan Capital Series A Cumulative Convertible Preferred Stock On January 26, 2005, we entered into a securities purchase agreement with Toucan Capital
pursuant to which they purchased 32.5 million shares of our newly designated series A preferred
stock at a purchase price of $0.04 per share, for a net purchase price of $1.276 million, net of
issue related costs of approximately $24,000. The series A preferred
stock:  (i)
    is entitled to cumulative dividends at the rate of 10% per year;(ii)
    is entitled to a liquidation preference in the amount of its initial purchase price
plus all accrued and unpaid dividends (to the extent of legally available funds);(iii)
    has a preference over the common stock with respect to dividends and distributions;(iv)
    is entitled to participate on an as-converted basis with the common stock on any
distributions after the payment of any preferential amounts to the series A stock; 10




---



##### Table of Contents



(v)
    votes on an as converted basis with the common stock on matters submitted to the common
stockholders for approval and as a separate class on certain other material matters; and(vi)
    is convertible into common stock on a one-for-one basis (subject to adjustment in the
event of stock dividends, stock splits, reverse stock splits, recapitalizations, etc.). The number of shares of common stock issuable upon conversion of each share of series A stock
is also subject to increase in the event of certain dilutive issuances in which we sell or are
deemed to have sold shares below the then applicable conversion price (currently $0.04 per share).
The consent of the holders of a majority of the series A preferred stock is required in the event
that we elect to undertake certain significant business actions. Toucan Capital Series A Warrant On January 26, 2005, we issued Toucan Capital a warrant, with a contractual life of 7-years,
to purchase 13.0 million shares of series A preferred stock, with an exercise price of $0.04 per
share, in connection with Toucan Capitals purchase of series A preferred stock on January 26,
2005. The number of shares issuable pursuant to the exercise of the warrant and the exercise price
thereof is subject to adjustment in the event of stock splits, reverse stock splits, stock
dividends, dilutive events and the like. 6. Subsequent Events On April 12, 2005, we borrowed an additional $450,000 from Toucan Capital and issued
warrants to purchase up to 4.5 million additional shares of our capital stock. The warrant,
with a contractual life of 7-years, has an exercise price of $0.04 per share. The number of
shares issuable pursuant to the exercise of the warrant and the exercise price thereof is
subject to adjustment in the event of stock splits, reverse stock splits, stock dividends,
dilutive events and the like. On May 13, 2005, we borrowed an additional $450,000 from Toucan Capital and issued warrants to
purchase up to 4.5 million additional shares of our capital stock. The warrant, with a contractual
life of 7-years, has an exercise price of $0.04 per share. The number of shares issuable pursuant
to the exercise of the warrant and the exercise price thereof is subject to adjustment in the event
of stock splits, reverse stock splits, stock dividends, dilutive events and the like. 7. Contingency On January 7, 2000, we qualified for the State of Washingtons (Chapter 82.63 Revised Code of
Washington) use tax deferral program for businesses engaged in high technology and research and
development activities. Under the deferral program, a business may defer paying sales and use tax
upon investments in qualified buildings, qualified machinery and equipment, or pilot scale
manufacturing. No repayment of the taxes deferred under this program is required if the business
uses the investment project for qualified research and development during the calendar year the
investment project is certified by the State of Washingtons Department of Revenue as operationally
complete, and for an additional seven calendar years. Beginning on October 9, 2002, we initiated a series of substantial steps to conserve cash,
including the relocation and consolidation of our facilities. On June 30, 2003, future lease
obligations of approximately $9.1 million were eliminated through the termination of our prior
lease when moving to a smaller facility. However, through abandoning the tenant improvements at the
prior facility, on which use tax payments to the State of Washington had been deferred, including
the disposal and impairment of previously qualified tax deferred equipment, we received a tax
assessment of $491,802 on October 21, 2003. The tax assessment payment was initially due on
November 20, 2003. This assessment, and accrued interest, is being carried as an estimated
liability on the balance sheet as of March 31, 2005 and is included in general and administrative
expense. The Company appealed this assessment and does not expect final resolution of this matter
until late 2005. In February 2004, we filed a refund request of approximately $175,000 related to certain other
state taxes to the State of Washingtons Department of Revenue. The finalization of this refund
request is expected to take several more months. 11




---



##### Table of Contents



Item. 2. Managements Discussion and Analysis of Financial Condition and Result of Operations The following discussion and analysis of our financial condition and results of operations
should be read in conjunction with our financial statements and the notes to those statements
included with this report. In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking
statements are subject to certain risks and uncertainties that could cause actual results to differ
materially from those projected. The words believe, expect, intend, anticipate, and similar
expressions are used to identify forward-looking statements, but some forward-looking statements
are expressed differently. Many factors could affect our actual results, including those factors
described under Factors That May Affect Results of Operations and Financial Condition. These
factors, among others, could cause results to differ materially from those presently anticipated by
us. You should not place undue reliance on these forward-looking statements. Overview We are a development stage biotechnology company focused on discovering, developing, and
commercializing immunotherapy products that safely generate and enhance immune system responses to
effectively treat cancer. Our primary activities since incorporation have been focused on
advancing a proprietary dendritic cell immunotherapy for prostate and brain cancer together with
strategic and financial planning, and raising capital to fund our operations. We completed an
initial public offering of our common stock in December 2001. Since 2002, we have only been able to obtain enough capital resources to pursue our strategic
plans at a very minimal level. We presently have approval from the U.S. Food and Drug
Administration, or FDA, to conduct a Phase III trial for DCVax-Prostate, our product candidate for
a possible prostate cancer treatment and a Phase II clinical trial to evaluate our
DCVax-Brain product candidate as a possible treatment for Glioblastoma Multiforme. However we do
not presently have adequate resources to conduct either of those trials. During 2004 and to date in 2005, we have undergone a significant recapitalization pursuant to
which Toucan Capital Fund II, L.P. has loaned us $5.25 million and invested $1.3 million in equity,
in return for debt securities, preferred stock and warrants. As
of May 13, 2005, we had cash of approximately $524,000 which we
believe will be sufficient to cover short-term payables to
approximately June 15, 2005, exclusive of the aggregate loan
repayments due Toucan Capital. In addition, we have a $500,000 note (plus accrued interest)
from Toucan Capital maturing on June 11, 2005 and additional notes from
Toucan Capital in aggregate principal amount of $600,000 (plus accrued
interest) maturing on June 26, 2005.  We are in discussions with
Toucan Capital to negotiate a potential extension of these obligations,
but we may not be able to do so.  If we fail to
negotiate an extension or make other arrangements to refinance these
obligations, we will need additional financing on or before
June 11, 2005 in order to satisfy these obligations.  There can be no
assurance that such additional financing would be available on
acceptable terms, or at all.
We will have to seek additional funds
from Toucan Capital, which Toucan Capital is not obligated to provide
us. Any additional financing with Toucan Capital and any third party
is likely to be dilutive to stockholders, and debt financing, if
available, may include additional restrictive covenants. Our
financial statements for the year ended December 31, 2004 and
three months ended March 31,
2005 were prepared on a going concern basis, which contemplates the realization of assets and the
settlement of liabilities in the normal course of business. Nevertheless, we have experienced
recurring losses from operations since inception, have a working capital deficit of $6.6 million,
and have a deficit accumulated during the development stage of $75.3 million, as of March 31, 2005,
that raises substantial doubt about our ability to continue as a going concern and our auditors
have issued an opinion on the December 31, 2004 financial statements which states that there is
substantial doubt about our ability to continue as a going concern. Critical Accounting Policies and Estimates Accounting principles generally accepted in the United States of America require our
management to make estimates and assumptions that affect the amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of our financial statements, as well as
the amounts of revenues and expenses during periods covered by our financial statements. The actual
amounts of these items could differ materially from those estimates. We also determine our employee stock option compensation costs as the difference between the
estimated fair value of our common stock and the exercise price of options on their date of grant.
Prior to our initial public offering, our common stock was not actively traded. The fair value of
our common stock for purposes of determining compensation expense for this period was determined
based on our review of the primary business factors underlying the value of our common stock on the
date such option grants were made, viewed in light of the expected initial public offering price
per share prior to the initial public offering of our common stock. The actual initial public
offering price was significantly lower than the expected price used in determining compensation
expense. Also, on an ongoing basis the estimate of expense for stock options and warrants
is dependant on factors such as expected life and volatility of our stock. To the extent actual
expense is different than that estimated, the actual expense that would have been recorded may be
substantially different 12




---



##### Table of Contents



In December 2004, the Financial Accounting Standards Board issued Statement of Financial
Accounting Standards No. 123 (revised 2004), (SFAS 123R), Share-Based Payment. Effective with our
fiscal year ending December 31, 2006, SFAS 123R requires the measurement of cost of
employee services received in exchange for an award of an equity instrument, such as stock options,
based on the grant-date fair-value of the award. The associated cost must be recognized over the
period during which an employee is required to provide service in exchange for the award (usually
the vesting period). SFAS 123R provides for a variety of implementation alternatives, including
accounting for the change prospectively or restating previously reported amounts to reflect the
compensation expense that would have been recorded under SFAS 123R. We are in the process of
determining the impact of SFAS 123R on our financial statements, including which implementation
alternative we will select. SFAS No. 151, Inventory Costs an amendment of ARB No. 43, Chapter 4 deals with inventory
pricing with respect to abnormal amounts of idle facility expenses, freight, handling costs, and
spoilage. Management is analyzing the requirements of this new Statement and believes that its
adoption will not have any significant impact on the Companys financial statements. SFAS No. 153, Exchanges of Nonmonetary Assets amends Opinion 29 to eliminate the exception for
nonmonetary exchanges of similar productive assets and replaces it with a general exception for
exchanges of nonmonetary assets that do not have commercial substance. Management is analyzing the
requirements of this new standard and believes that its adoption will not have any significant
impact on the Companys financial statements. FIN No. 46(R) revised FIN No. 46, Consolidation of Variable Interest Entities, requiring the
consolidation by a business of variable interest entities in which it is the primary beneficiary.
The adoption of FIN No. 46 did not have an impact on the Companys financial statements. The Emerging Issues Task Force (EITF) reached consensus on Issue No. 03-1, The Meaning of
Other-Than-Temporary Impairment and Its Application to Certain Investments (EITF 03-1) which
provides guidance on determining when an investment is considered impaired, whether that impairment
is other than temporary and the measurement of an impairment loss. The FASB issued FSP EITF 03-1-1,
Effective Date of Paragraphs 10-20 of EITF Issue No. 03-1, The Meaning of Other-Than-Temporary
Impairment and Its Application to Certain Investments"', which delays the effective date for the
measurement and recognition criteria contained in EITF 03-1 until final application guidance is
issued. The Company does not expect the adoption of this consensus or FSP to have a material impact
on its financial statements. The EITF reached a consensus on Issue No. 04-8, The Effect of Contingently Convertible Debt
on Diluted Earnings Per Share (EITF 04-8), which addresses when the dilutive effect of
contingently convertible debt instruments should be included in diluted earnings (loss) per share.
EITF 04-8 is effective for reporting periods ending after December 15, 2004. The adoption of EITF
04-8 did not have an impact on diluted earnings (loss) per share. Results of Operations Operating costs and expenses consist primarily of research and development expenses, including
clinical trial expenses when we are is actively participating in clinical trials, and general and
administrative expenses. Research and development expenses include salary and benefit expenses and costs of laboratory
supplies used in our internal research and development projects. From our inception
through March 31, 2005, we incurred costs of approximately $28.9 million associated with our
research and development activities. Because our technologies are unproven, we are unable to
estimate with any certainty the costs we will incur in the continued development of our product
candidates for commercialization. General and administrative expenses include salary and benefit expenses related to
administrative personnel, cost of facilities, insurance, legal support, as well as amortization
costs of stock options granted to employees and warrants issued to consultants. 13




---



##### Table of Contents



Three Months Ended March 31, 2004 and 2005 Total Revenues.Revenues decreased 32% from $127,000 for the three months ended March 31, 2004
to $87,000 for the three months ended March 31, 2005. The research material sales component of
revenue decreased 54% from $24,000 for the three months ended March 31, 2004 to $11,000 for the
three months ended March 31, 2005. Research grant income decreased 26% from $103,000 for the three
months ended March 31, 2004 to $76,000 for the three months ended March 31, 2005. This decrease in
grant revenue was attributable to the cessation of the remaining two research grant awards during
the first quarter of 2005. Cost of Research Material Sales.Cost of research material sales decreased 92% from $25,000
for the three months ended March 31, 2004 to $2,000 for the three months ended March 31, 2005.
This lower sales volume resulted primarily from lower direct advertising in select trade journals
in the first quarter 2005. We are unable to project when, if ever, our sales of research materials
will attain consistent profitability. Research and Development Expense.Research and development expense increased from $229,000 for
the three months ended March 31, 2004 to $1.3 million for the three months ended March 31, 2005.
This increase was primarily due to increased expenditures for consultants in preparation of and
filing an IND with the FDA and for entering into a service agreement for drug manufacturing,
regulatory advice, and research and development related to preclinical activities. General and Administrative Expense.General and administrative expense decreased 17% from
$557,000 for the three months ended March 31, 2004 to $464,000 for the three months ended March
31, 2005. This decrease was primarily due to the October 9, 2002 directive from our Board of
Directors to initiate immediate actions to conserve cash and the resulting staff reductions. Depreciation and Amortization.Depreciation and amortization decreased 35% from $37,000 the
three months ended March 31, 2004 to $24,000 for the three months ended March 31, 2005. This
decrease was primarily due to the disposal or impairment of $337,000 of property and equipment in
the third and fourth quarters 2004. Total Other Income (Expense), Net.Interest expense increased from $107,000 for the three
months ended March 31, 2004 to $809,000 for the three months ended March 31, 2005. This increase
was due primarily to recognizing interest expense relative to the debt discount and interest
accretion associated with the secured convertible promissory notes and warrants debt financing. Liquidity and Capital Resources On January 7, 2000, we qualified for the State of Washingtons use tax deferral program for
businesses engaged in high technology and research and development activities. Under the deferral
program, a business may defer paying sales and use tax upon investments in qualified buildings,
qualified machinery and equipment, or pilot scale manufacturing. No repayment of the taxes deferred
under this program is required if the business uses the investment project for qualified research
and development during the calendar year the investment project is certified by the State of
Washingtons Department of Revenue as operationally complete, and for an additional seven calendar
years. Beginning on October 9, 2002, we initiated a series of substantial steps to conserve cash,
including the relocation and consolidation of our facilities. We received a tax assessment of
$491,802 on October 21, 2003 due to our abandonment of tenant improvements at the prior facility,
on which use tax payments had been deferred, including the disposal and impairment of previously
qualified tax deferred equipment. The tax assessment payment was initially due on November 20,
2003. This assessment, and accrued interest, is being carried as an estimated liability on our
balance sheet as of March 31, 2005 and is included in general and administrative expense. We have
appealed this assessment and do not expect final resolution of this matter until late 2005. In February 2004, we filed a refund request of approximately $175,000 related to certain state
taxes previously paid to the State of Washington. The finalization of this refund request is
expected to take several more months. From
February 1, 2004 through May 13, 2005, we borrowed
$5.25 million from Toucan Capital. Toucan Capital has the right,
as of May 14, 2005, to convert principal and interest on the
loans to acquire up to approximately 139.6 million shares of our
capital stock and has the right to acquire up to approximately
120.5 million shares upon exercise of related warrants,
inclusive of the 13.0 million series A warrants. Including
the 32.5 million shares of series A preferred stock held by Toucan
Capital, they have beneficial ownership of approximately
292.6 million shares of our capital stock, representing a as-converted beneficial ownership of approximately 93.9% of our common
stock. Toucan Capital has a right of first refusal to participate in
our future issuances of debt or equity securities. 14




---



##### Table of Contents



As
of May 13, 2005, we had cash of approximately $524,000 which we
believe will be sufficient to cover short-term payables to
approximately June 15, 2005, exclusive of the aggregate loan
repayments due Toucan Capital. In addition, we have a $500,000 note (plus accrued interest)
from Toucan Capital maturing on June 11, 2005 and additional notes from
Toucan Capital in aggregate principal amount of $600,000 (plus accrued
interest) maturing on June 26, 2005.  We are in discussions with
Toucan Capital to negotiate a potential extension of these obligations,
but we may not be able to do so.  If we fail to
negotiate an extension or make other arrangements to refinance these
obligations, we will need additional financing on or before
June 11, 2005 in order to satisfy these obligations.  There can be no
assurance that such additional financing would be available on
acceptable terms, or at all.  We will have to seek additional funds
from Toucan Capital, which Toucan Capital is not obligated to provide
us. Any additional financing with Toucan Capital and any third party
is likely to be dilutive to stockholders, and debt financing, if
available, may include additional restrictive covenants. If we are unable to obtain significant additional capital in the near-term, we may cease
operations at anytime. We do not believe that our assets would be sufficient to satisfy the claims
of all of our creditors in full. Therefore, if we were to pursue a liquidation it is highly
unlikely that any proceeds would be received by our stockholders. Our independent auditors have indicated in their report on our financial statements, included
in our December 31, 2004 annual report on Form 10-K, that there is substantial doubt about our
ability to continue as a going concern. We need to raise significant additional funding to continue
our operations, conduct research and development activities, pre-clinical studies and clinical
trials necessary to bring our product candidates to market. However, additional funding may not be
available on terms acceptable to us or at all. The alternative of issuing additional equity or
convertible debt securities also may not be available and, in any event, would result in additional
dilution to our stockholders. Sources of Cash Federal Grants On April 8, 2003, we were awarded a NIH cancer research grant. The total first year grant
award was approximately $318,000, was earned under the grant, and was recognized in revenue through
the year ended December 31, 2003. The total award for fiscal 2004  2005 was approximately
$328,000, comprised of approximately $198,000 authorized for direct grant research expenditures and
approximately $130,000 authorized for use to cover our facilities and administrative overhead
costs. This grants remaining $35,000 award was recognized in January 2005. This grant ended
January 31, 2005. Effective September 10, 2004, we were awarded a small business innovation research grant. The
grant award for $100,000 had an award period that commenced September 10, 2004. There was
approximately $59,000 earned under the grant and recognized in revenue through the year ended
December 31, 2004, with the remaining $41,000 of the grants aggregate award recognized through the
three months ended March 31, 2005. Research Reagent Sales On April 21, 2003, we announced our entry into the research reagents market. We earned
approximately $11,000 in revenue for the three months ended March 31, 2005 from the manufacture and
sale of research materials. We are unable to project when, if ever, our sales of research materials
will attain a consistent profitability. License Fees Our effort to license certain rights, title, and interest to technology
relating to the worldwide use of specific antibodies for the diagnostic immunohistochemical market
resulted in the July 1, 2003 license agreement with DakoCytomation California, Inc. with the
payment of a one-time $25,000 license fee and future non-refundable minimum annual royalty payments
of $10,000 credited against any royalty payments made to us. The $25,000 one-time license fee was
received on August 25, 2003. We waived the payment of the July 1, 2004 annual royalty payment
because of costs incurred by DakoCytomation, on our behalf, regarding purity issues with the
initial cell lines. Management Loan On November 13, 2003, we borrowed an aggregate of $335,000 from members of our management. The
notes accrue interest at an annual rate equal to the prime rate plus 2% and are payable by July 12,
2005 and were initially secured by substantially all of our assets not otherwise collateralized. We
repaid $50,000, including interest of $1,674, on June 1, 2004 and repaid an additional $50,000,
including interest of $4,497, on February 24, 2005. 15




---



##### Table of Contents



As part of the management loan, the lenders were issued warrants initially exercisable to
acquire an aggregate of 3.7 million shares of our common stock, expiring November 2008 subject to
certain antidilution adjustments, at an exercise
price to be determined as follows: (i) in the event that we completed an offering of our common
stock generating gross proceeds to us of at least $1 million, then the price per share paid by
investors in that offering; or (ii) if we did not complete such an offering, then $0.18, which was
the closing price of our common stock on the date of the financing. In connection with our April
26, 2004 recapitalization agreement these warrants were amended to remove the anti-dilution
provisions and set the warrant exercise price at the lesser of (i) $0.10 per share or (ii) a 35%
discount to the average closing price during the twenty trading days prior to the first closing of
the sale by us of convertible preferred stock as contemplated by the recapitalization agreement but
not less than $0.04 per share. Uses of Cash We used $260,000 in cash for operating activities during the three months ended March 31,
2004, compared to $1.5 million for the three months ended March 31, 2005. The increase in cash used
in operating activities from 2004 to 2005, was primarily the result of increased expenditures for
consultants in preparation of and filing an IND with the FDA and for entering into a service
agreement for drug manufacturing, regulatory advice, and research and development related to
preclinical activities. We generated $76,000 in cash from investing activities during the three months ended March 31,
2004 compared to $81,000 provided by investing activities during the three months ended March 31,
2005. The cash provided during the three months ended March 31, 2005 consisted of net proceeds
from the sale of property and equipment. We generated $89,000 in cash from financing activities for the three months ended March 31,
2004 primarily from the February 2 and March 1, 2004 loans, $50,000 each, from Toucan Capital. We
generated $1.2 million in cash from financing activities during the three months ended March 31,
2005 consisting primarily of the January 26, 2005 securities purchase agreement with Toucan Capital
pursuant to which they purchased 32.5 million shares of our newly designated series A preferred
stock at a purchase price of $0.04 per share, for a net purchase price of $1.276 million, net of
issue related costs of approximately $24,000. Factors That May Affect Results of Operations and Financial Condition This section briefly discusses certain risks that should be considered by our stockholders and
prospective investors. You should carefully consider the risks described below, together with all
other information included in our annual report on Form 10-K for the year ended December 31, 2004
and the information incorporated by reference. If any of the following risks actually occur, our
business, financial condition, or operating results could be harmed. In such case, you could lose
all of your investment. We will need to raise additional capital which may not be available. As
of May 13, 2005, we had cash of approximately $524,000 which we
believe will be sufficient to cover short-term payables to
approximately June 15, 2005, exclusive of the aggregate loan
repayments due Toucan Capital. In addition, we have a $500,000 note (plus accrued interest)
from Toucan Capital maturing on June 11, 2005 and additional notes from
Toucan Capital in aggregate principal amount of $600,000 (plus accrued
interest) maturing on June 26, 2005.  We are in discussions with
Toucan Capital to negotiate a potential extension of these obligations,
but we may not be able to do so.  If we fail to
negotiate an extension or make other arrangements to refinance these
obligations, we will need additional financing on or before
June 11, 2005 in order to satisfy these obligations.  There can be no
assurance that such additional financing would be available on
acceptable terms, or at all.  We will have to seek additional funds
from Toucan Capital, which Toucan Capital is not obligated to provide
us. Any additional financing with Toucan Capital and any third party
is likely to be dilutive to stockholders, and debt financing, if
available, may include additional restrictive covenants. If we are unable to obtain significant additional capital in the near-term, we may cease operations
at anytime. We do not believe that our assets would be sufficient to satisfy the claims of all of
our creditors in full. Therefore, if we were to pursue a liquidation it is highly unlikely that any
proceeds would be received by our stockholders. Our auditors have issued a going concern audit opinion. Our independent auditors have indicated in their report on our December 31, 2004 financial
statements that there is substantial doubt about our ability to continue as a going concern. A
going concern opinion indicates that the financial statements have been prepared assuming we will
continue as a going concern and do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of
liabilities that may result from the outcome of this uncertainty. Therefore, you should not rely on
our consolidated balance sheet as an 16




---



##### Table of Contents



indication of the amount of proceeds that would be available
to satisfy claims of creditors, and potentially be available for distribution to stockholders, in
the event of a liquidation. We expect to continue to incur substantial losses, and we may never achieve profitability. We have incurred net losses every year since our incorporation in July 1998 and, as of March
31, 2005, we had a deficit accumulated during the development stage of approximately $75.3 million.
We have had net losses applicable to common stockholders as follows:  
    $12.8 million in 2002;
    $5.8 million in 2003; and
    $8.6 million in 2004. We expect that these losses will continue, and anticipate negative cash flows from operations
for the foreseeable future. Because of our current cash position, we will need to secure additional
funding to continue operations. In addition, we will need to generate revenue sufficient to cover
operating expenses and research and development costs to achieve profitability. We may never
achieve or sustain profitability. As a company in the early stage of development with an unproven business
strategy, our limited history of operations makes an evaluation of our business
and prospects difficult. We have had a limited operating history and are still in development. We may not be able to
achieve revenue growth in the future. We have generated the following limited revenues:  
    $9,000 in 2002;
    $529,000 in 2003; and
    $390,000 in 2004. We have derived most of these limited revenues from:  
    the sale of research products to a single customer;
    contract research and development from related parties; and
    research grants. In the future, we anticipate that revenues, if any, will be derived through grants, partnering
agreements, and, ultimately, the commercialization of our product candidates. We have reduced business umbrella, auto, crime and fiduciary, and directors and officers liability insurance coverage. Due to rising insurance premiums for most business insurance coverage, our
reduced level of operating activity, and reduced liability exposure through the cessation of all
clinical trials, we lowered the levels of all of our insurance coverage. Making a material
reduction in our insurance coverage may make it difficult for us to acquire new directors and
officers, and will also result in increased exposure to potential liabilities arising from any
future litigation, either of which may materially harm our business and results of operations. We may not be able to retain or recruit personnel. 17




---



##### Table of Contents



Since September 2002, we reduced our research and administrative staff approximately 94%, from
67 employees to a remaining staff of four full-time employees, as of May 14, 2005. The uncertainty
of our cash position, workforce reductions, the volatility in our stock price and our recent asset
sales may create anxiety and uncertainty, which may adversely affect employee morale and cause us
to lose employees whom we would prefer to retain or prevent us from hiring qualified staff. To the
extent that we are unable to retain our existing personnel, our business and financial results may
suffer. Failure to obtain regulatory approval for one or more of our product candidates could
significantly harm our business. All of our product candidates are still under development. None of our product candidates will
be commercially available prior to FDA approval. Significant further financial resources and
personnel will be required to develop commercially viable products and obtain regulatory approvals.
Much of our efforts and expenditures over the next few years will be devoted to completing the last
clinical trials and seeking FDA approval for our lead product candidates, DCVax-Prostate and
DCVax-Brain. Success in pre-clinical studies and prior clinical trials does not ensure that subsequent
large-scale trials will likewise be successful, nor is it a basis for predicting final results. A
number of companies in the biotechnology industry have suffered significant setbacks in advanced
clinical trials, even after promising
results have been achieved in earlier trials. Failure to obtain Food and Drug Administration, or
FDA, approval for one or more of our product candidates could significantly harm our business. We have no manufacturing capabilities, which could adversely impact our ability
to commercialize our product candidates. We have no manufacturing facilities nor expertise to produce our product candidates. We have
never manufactured, on a commercial scale, any of our product candidates. We currently have
manufacturing arrangements in place with a contract manufacturer (Cognate Therapeutics). However,
we may not be able to enter into agreements with contract manufactures for the manufacture of any
of our product candidates at a reasonable cost or in sufficient quantities to be profitable. Because we lack sales and marketing experience, we may experience significant
difficulties commercializing our research product candidates. The commercial success of any of our product candidates will depend upon the strength of our
sales and marketing efforts. We do not have a sales force and have no experience in the sales,
marketing or distribution of products. To fully commercialize our product candidates, we will need
to create a substantial marketing staff and sales force with technical expertise and the ability to
distribute these products. As an alternative, we could seek assistance from a third party with a
large distribution system and a large direct sales force. We may be unable to put either of these
plans in place. In addition, if we arrange for others to market and sell our products, our revenues
will depend upon the efforts of those parties. Such arrangements may not succeed. If we fail to
establish adequate sales, marketing and distribution capabilities, independently or with others,
our business will be seriously harmed. Our success partially depends on existing and future partners. The success of our business strategy may partially depend upon our ability to develop and
maintain multiple partnerships and to manage them effectively. The success of our restructured
operations will depend on our ability to attract partners to our research initiatives. Due to
concerns regarding our ability to continue operations, these third parties may decide not to
conduct business with us, or may conduct business with us on terms that are less favorable than
those customarily extended by them. If either of these events occurs, our business will suffer
significantly. Our success depends partially upon the performance of our partners. We cannot directly control
the amount and timing of resources that our existing or future partners devote to the research,
development or marketing of our product candidates. As a result, those partners:  
    may not commit sufficient resources to our programs or product candidates;
    may not conduct their agreed activities on time, or at all, resulting in delay or
termination of the development of our product candidates and technology; 18




---



##### Table of Contents




    may not perform their obligations as expected;
    may pursue products or alternative technologies in preference to ours; or
    may dispute the ownership of products or technology developed under our partnerships. We may have disputes with our partners, which could be costly and time
consuming. Our failure to successfully defend our rights could seriously harm our business,
financial condition and operating results. We intend to continue to enter into partnerships in the
future. However, we may be unable to successfully negotiate any additional partnerships and any of
these relationships, if established, may not be scientifically or commercially successful. We also
work with scientists and medical professionals at academic and other institutions, including the
University of California, Los Angeles, M.D. Anderson Cancer Center, and the H. Lee Moffitt Cancer
Center some of whom have conducted research for us or assist us in developing our research and
development strategy. These scientists and medical professionals are not our employees. They may
have commitments to, or contracts with, other businesses or institutions that limit the amount of
time they have available to work with us. We have little control over these individuals. We can
only expect them to devote to our projects the amount of time required by our license, consulting
and sponsored research agreements. In addition, these individuals may have arrangements with other
companies to assist in developing technologies that may compete with ours. If these individuals do
not devote sufficient time and resources to our programs, our business could be seriously harmed. Competition in our industry is intense and most of our competitors have substantially greater resources than we have. The biotechnology and biopharmaceutical industries are characterized by rapidly advancing
technologies, intense competition and a strong emphasis on proprietary products. Several companies,
such as Cell Genesys, Inc., Dendreon Corporation and Immuno-Designed Molecules, Inc., are actively
involved in the research and development of cell-based cancer therapeutics. Additionally, several
companies, such as Abgenix, Inc., Agensys, Inc., and Genentech, Inc., are actively involved in the
research and development of monoclonal antibody-based cancer therapies. Currently, at least seven
antibody-based products are approved for commercial sale for cancer therapy. Genentech is also
engaged in several Phase III clinical trials for additional antibody-based therapeutics for a
variety of cancers, and several other companies are in early stage clinical trials for such
products. Many other third parties compete with us in developing alternative therapies to treat
cancer, including:  
    biopharmaceutical companies;
    biotechnology companies;
    pharmaceutical companies;
    academic institutions; and
    other research organizations. Many of our competitors have significantly greater financial resources and expertise in
research and development, manufacturing, pre-clinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing than we do. In addition, many of these competitors
have become active in seeking patent protection and licensing arrangements in anticipation of
collecting royalties for use of technology they have developed. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining
qualified scientific and management personnel, as well as in acquiring technologies complementary
to our programs. We expect that our ability to compete effectively will be dependent upon our ability to:  
    obtain additional funding;
    successfully complete clinical trials and obtain all requisite regulatory approvals;
    maintain a proprietary position in our technologies and products; 19




---



##### Table of Contents




    attract and retain key personnel; and
    maintain existing or enter into new partnerships. Our competitors may develop more effective or affordable products, or achieve earlier patent
protection or product marketing and sales than we may. As a result, any products we develop may be
rendered obsolete and noncompetitive. Our intellectual property rights may not provide meaningful commercial
protection for our research products or product candidates, which could enable
third parties to use our technology, or very similar technology, and could
reduce our ability to compete in the market. We rely on patent, copyright, trade secret and trademark laws to limit the ability of others
to compete with us using the same or similar technology in the United States and other countries.
However, as described below, these laws afford only limited protection and may not adequately
protect our rights to the extent necessary to sustain any competitive advantage we may have. The
laws of some foreign countries do not protect proprietary rights to the same extent as the laws of
the United States, and we may encounter significant problems in protecting our proprietary rights
in these countries. We
have 15 issued and licensed patents (eight in the United States and seven in foreign
jurisdictions) and 104 patent applications pending (18 in the United States and 86 in foreign
jurisdictions) which cover the use of dendritic cells in DCVax as well as targets for either our
dendritic cell or fully human monoclonal antibody therapy candidates. The issued patents expire at
dates from 2015 to 2018. We will only be able to protect our technologies from unauthorized use by third parties to the
extent that they are covered by valid and enforceable patents or are effectively maintained as
trade secrets. The patent positions of companies developing novel cancer treatments, including our
patent position, generally are uncertain and involve complex legal and factual questions,
particularly concerning the scope and enforceability of claims of such patents against alleged
infringement. Recent judicial decisions are prompting a reinterpretation of the limited case law
that exists in this area, and historical legal standards surrounding questions of infringement and
validity may not apply in future cases. A reinterpretation of existing law in this area may limit
or potentially eliminate our patent position and, therefore, our ability to prevent others from
using our technologies. The biotechnology patent situation outside the United States is even more
uncertain. Changes in either the patent laws or in interpretations of patent laws in the United
States and other countries may therefore diminish the value of our intellectual property. We own or have rights under licenses to a variety of issued patents and pending patent
applications. However, the patents on which we rely may be challenged and invalidated, and our
patent applications may not result in issued patents. Moreover, our patents and patent applications
may not be sufficiently broad to prevent others from practicing our technologies or from developing
competing products. We also face the risk that others may independently develop similar or
alternative technologies or design around our patented technologies. We have taken security measures to protect our proprietary information. These measures,
however, may not provide adequate protection of our trade secrets or other proprietary information.
We seek to protect our proprietary information by entering into confidentiality agreements with
employees, partners and consultants. Nevertheless, employees, partners or consultants may still
disclose our proprietary information, and we may not be able to protect our trade secrets in a
meaningful way. If we lose any employees, we may not be able to prevent the unauthorized disclosure
or use of our technical knowledge or other trade secrets by those former employees despite the
existence of nondisclosure and confidentiality agreements and other contractual restrictions to
protect our proprietary technology. In addition, others may independently develop substantially
equivalent proprietary information or techniques or otherwise gain access to our trade secrets. Our success will depend partly on our ability to operate without infringing or
misappropriating the proprietary rights of others. Our success will depend to a substantial degree upon our ability to develop, manufacture,
market and sell our research products and product candidates without infringing the proprietary
rights of third parties and without breaching any licenses we have entered into regarding our
product candidates. There is a substantial amount of litigation involving patent and other
intellectual property rights in the biotechnology and biopharmaceutical industries generally.
Infringement and other intellectual property claims, with or without merit, can be expensive and
time-consuming to litigate and can divert 20




---



##### Table of Contents



managements attention from our core business. We may be exposed to future litigation by third
parties based on claims that our products infringe their intellectual property rights. This risk is
exacerbated by the fact that there are numerous issued and pending patents in the biotechnology
industry and the fact that the validity and breadth of biotechnology patents involve complex legal
and factual questions for which important legal principles remain unresolved. Third parties may assert that our products and the methods we employ are covered by U.S. or
foreign patents held by them. In addition, because patent applications can take many years to
issue, there may be currently pending applications, unknown to us, which may later result in issued
patents that we may infringe. There could also be existing patents of which we are not aware that
we may inadvertently infringe. If we lose a patent infringement lawsuit, we could be prevented from commercialing product
candidates unless we can obtain a license to use technology or ideas covered by such patent or are
able to redesign our products to avoid infringement. A license may not be available at all or on
terms acceptable to us, or we may not be able to redesign our products to avoid any infringement.
If we are not successful in obtaining a license or redesigning our products, we may be unable to
commercialing our product candidates and our business could suffer. We use hazardous materials and must comply with environmental, health and
safety laws and regulations, which can be expensive and restrict how we do
business. We store, handle, use and dispose of controlled hazardous, radioactive and biological
materials in our business. Our current use of these materials generally is below thresholds giving
rise to burdensome regulatory requirements. Our development efforts, however, may result in our
becoming subject to additional requirements, and if we fail to comply with applicable requirements
we could be subject to substantial fines and other sanctions, delays in research and production,
and increased operating costs. In addition, if regulated materials were improperly released at our
current or former facilities or at locations to which we send materials for disposal, we could be
strictly liable for substantial damages and costs, including cleanup costs and personal injury or
property damages, and incur delays in research and production and increased operating costs. Insurance covering certain types of claims of environmental damage or injury resulting from
the use of these materials is available but can be expensive and is limited in its coverage. We
have no insurance specifically covering environmental risks or personal injury from the use of
these materials and if such use results in liability, our business may be seriously harmed. Toucan Capital owns the vast majority of
our stock and, as a result, the trading price for our shares may be
depressed as they can take actions that may be adverse to your interests. From
February 1, 2004 through May 13, 2005, we borrowed
$5.25 million from Toucan Capital. Toucan Capital has the right,
as of May 14, 2005, to convert principal and interest on the
loans to acquire up to approximately 139.6 million shares of our
capital stock and has the right to acquire up to approximately 120.5 million shares upon
exercise of related warrants, inclusive of the 13.0 million
series A warrants. Including the 32.5 million of
series A preferred stock held by Toucan Capital, they have
beneficial ownership of approximately 292.6 million shares of
our capital stock, representing a as-converted beneficial ownership
of approximately 93.9% of our common stock. The
notes held by Toucan Capital are currently convertible into common
stock or series A preferred stock at Toucans election, at
the price of $0.04 per share and the series A stock is similarly
convertible into common stock. Finally, the warrants held by Toucan
are exercisable at exercise prices ranging from $0.01 to $0.04 per
share. This significant concentration of ownership may adversely
affect the trading price for our common stock because investors
often perceive disadvantages in owning stock in companies with
controlling stockholders. Company management and Toucan Capital, have
the ability to exert substantial influence over all matters requiring
approval by our stockholders, including the election and removal of
directors and any proposed merger, consolidation or sale of all or
substantially all of our assets. In addition, they can dictate the
management of our business and affairs. This concentration of
ownership could have the effect of delaying, deferring or preventing
a change in control, or impeding a merger or consolidation, takeover
or other business combination that could be favorable to you. There may not be an active, liquid trading market for our common stock. On December 14, 2001, our common stock was listed on the NASDAQ National Market. Prior to that
time there was no public market for our common stock. On December 23, 2002, we were delisted from
the NASDAQ National Market and our common stock is currently listed on the Over The Counter
Bulletin Board (OTCBB), which is generally recognized as being a less active market than the NASDAQ
National Market. You may not be able to sell your shares at the time or at the price desired. Our common stock may experience extreme price and volume fluctuations, which
could lead to costly litigation for us and make an investment in us less
appealing. 21




---



##### Table of Contents



The market price of our common stock may fluctuate substantially due to a variety of factors,
including:  
    announcements of technological innovations or new products by us or our competitors;
    development and introduction of new cancer therapies;
    media reports and publications about cancer therapies;
    announcements concerning our competitors or the biotechnology industry in general;
    new regulatory pronouncements and changes in regulatory guidelines;
    general and industry-specific economic conditions;
    changes in financial estimates or recommendations by securities analysts; and
    changes in accounting principles. The market prices of the securities of biotechnology companies, particularly companies like
ours without earnings and consistent product revenues, have been highly volatile and are likely to
remain highly volatile in the future. This volatility has often been unrelated to the operating
performance of particular companies. In the past, securities class action litigation has often been
brought against companies that experience volatility in the market price of their securities.
Moreover, market prices for stocks of biotechnology-related and technology companies occasionally
trade at levels that bear no relationship to the operating performance of such companies. These
market prices generally are not sustainable and are subject to wide variations. Whether or not
meritorious, litigation brought against us could result in substantial costs, divert managements
attention and resources and harm our financial condition and results of operations. Our incorporation documents, bylaws and stockholder rights plan may delay or prevent a change in our management. Our amended and restated certificate of incorporation, bylaws and stockholder rights plan
contain provisions that could delay or prevent a change in our management team. Some of these
provisions:  
    authorize the issuance of preferred stock that can be created and issued by the board of
directors without prior stockholder approval, commonly referred to as blank check preferred
stock, with rights senior to those of common stock;
    authorize our board of directors to issue dilutive shares of common stock upon certain events; and
    provide for a classified board of directors. These provisions could allow our board of directors to affect your rights as a
stockholder since our board of directors can make it more difficult for common stockholders to
replace members of the board. Because our board of directors is responsible for appointing the
members of our management team, these provisions could in turn affect any attempt to replace our
current management team. Toucan Capital has the ability to control our company. From February 1, 2004 through May 13, 2005, we borrowed $5.25 million from Toucan Capital.
Toucan Capital has the right, as of May 14, 2005, to convert principal and interest on the loans to
acquire up to approximately 139.6 million shares of our capital stock and has the right to acquire
up to approximately 120.5 million shares upon exercise of related warrants, inclusive of the 13.0
million series A warrants. Including the 32.5 million of series A preferred stock held by Toucan
Capital, they have beneficial ownership of approximately 292.6 million shares of our capital stock,
representing a as-converted beneficial ownership of approximately
93.9% of our common stock. Toucan Capital has a right of
first refusal to participate in our future issuances of debt or equity securities. 22




---



##### Table of Contents



In addition, under the terms of our recapitalization agreement, we are required to consult
with Toucan Capital on how we conduct many aspects of our business. As a result, Toucan Capital has
significant authority over how we conduct our business, and with its stock acquisition rights,
could influence or control all matters requiring stockholder approval. This control may cause us to
conduct our business differently from the way we have in the past. The concentration of ownership
may also delay, deter or prevent acts that would result in a change in control, which, in turn,
could reduce the market price of our common stock. Our incorporation documents, bylaws and stockholder rights plan may delay or prevent a change in
our management. Our amended and restated certificate of incorporation, bylaws and stockholder rights plan contain
provision that could delay or prevent a change in our management team. Some of these provisions:  
    authorize the issuance of preferred stock that can be created and issued by the board of directors without
prior stockholder approval, commonly referred to as blank check preferred stock, with rights senior to those of
common stock;
    authorize our board of directors to issue dilutive shares of common stock upon certain events; and
    provide for a classified board of directors. These provisions could allow our board of directors to affect your rights as a stockholder
since our board of directors can make it more difficult for common stockholders to replace members
of the board. Because our board of directors is responsible for appointing the members of our
management team, these provisions could in turn affect any attempt to replace our current
management team. 
 Item 3. Quantitative and Qualitative Disclosures About Market Risk Our exposure to market risk is presently limited to the interest rate sensitivity of our cash
and cash equivalents which is affected by changes in the general level of U.S. interest rates. We
are exposed to interest rate changes primarily as a result of our investment activities. The
primary objective of our investment activities is to preserve principal while at the same time
maximizing the income we receive without significantly increasing risk. To minimize risk, we
maintain our cash and cash equivalents in interest-bearing instruments, primarily money market
funds. Our interest rate risk management objective with respect to our borrowings is to limit the
impact of interest rate changes on earnings and cash flows. Due to the nature of our cash and cash
equivalents, we believe that we are not subject to any material market risk exposure. We do not
have any foreign currency or other derivative financial instruments. 
 Item 4. Controls and Procedures (a) Evaluation of disclosure controls, procedures, and internal controls Our president and our controller, after evaluating, as required, the effectiveness of our
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)),
recognized, as of March 31, 2005, our disclosure controls and procedures contained certain internal
control weaknesses that, in the aggregate, represent material weaknesses. The identified weaknesses were anticipated given the companys status with respect to its
number of employees (four full-time employees). The weaknesses were comprised of: insufficient
segregation of duties, insufficient corporate governance policies, and lack of independent
directors as of March 31, 2005. Each of these weaknesses is expected to be corrected with the
recapitalization of our company. SEC release #33-8545 extends the deadline for section 404
compliance for non-accelerated filers, such as our company, to the first fiscal year ending on or
after July 15, 2006. 23




---



##### Table of Contents



As part of the communications by Peterson Sullivan with our audit committee with respect to
Peterson Sullivans audit procedures for 2005, Peterson Sullivan informed the audit committee that
these deficiencies constituted material weaknesses, as defined by Auditing Standard No. 2 , An
Audit of Internal Control Over Financial Reporting Performed in Conjunction with an Audit of
Financial Statements, established by the Public Company
Accounting Oversight Board, or PCAOB. 
 Part II  Other Information 
 Item 1. Legal Proceedings We are presently party to an arbitration proceeding with Soma Partners, LLC, an investment
bank located in New Jersey. We were parties with Soma to an engagement letter dated October 15,
2003 pursuant to which we engaged them to locate potential investors. Pursuant to the terms of the
engagement letter, any disputes arising between the parties would be submitted to arbitration in
the New York metropolitan area. Soma filed an arbitration statement of claim against us with the
American Arbitration Association in New York, NY claiming unpaid commission fees of $186,000 and
seeking declaratory relief regarding potential fees for future transactions that may be undertaken
by us with Toucan Capital. Soma has filed an amended arbitration statement of claim claiming unpaid commission fees of
$339,000, as well as warrants to purchase 6% of the aggregate securities issued, and seeking
declaratory relief regarding potential fees for future financing transactions which may be
undertaken by us with Toucan Capital and others. If Soma were to prevail, the arbitrator could also
award its attorneys fees and costs related to the proceedings. The arbitrator might also award
declaratory relief to Soma regarding potential fees for future financing transactions that may be
undertaken by us with Toucan Capital and others. We strongly dispute Somas claims and are
defending ourselves. The arbitration proceedings occurred from March 8-10, 2005 and the arbitrator
has indicated he will issue his ruling before approximately May 25, 2005. 
 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Toucan Capital Series A Cumulative Convertible Preferred Stock On January 26, 2005, we entered into a securities purchase agreement with Toucan Capital
pursuant to which they purchased 32.5 million shares of our newly designated series A preferred
stock at a purchase price of $0.04 per share, for a net purchase
price of $1.276 million, net of
issue related costs of approximately $24,000. The series A
preferred stock:  (i)
    is entitled to cumulative dividends at the rate of 10% per year;(ii)
    is entitled to a liquidation preference in the amount of its initial purchase price
plus all accrued and unpaid dividends (to the extent of legally available funds);(iii)
    has a preference over the common stock with respect to dividends and distributions;(iv)
    is entitled to participate on an as-converted basis with the common stock on any
distributions after the payment of any preferential amounts to the series A stock;(v)
    votes on an as converted basis with the common stock on matters submitted to the common
stockholders for approval and as a separate class on certain other material matters; and(vi)
    is convertible into common stock on a one-for-one basis (subject to adjustment in the
event of stock dividends, stock splits, reverse stock splits, recapitalizations, etc.). The number of shares of common stock issuable upon conversion of each share of series A stock
is also subject to increase in the event of certain dilutive issuances in which we sell or are
deemed to have sold shares below the then applicable conversion price (currently $0.04 per share).
The consent of the holders of a majority of the series A preferred stock is required in the event
that we elect to undertake certain significant business actions. Toucan Capital Series A Warrant On January 26, 2005, we issued Toucan Capital a warrant, with a contractual life of 7-years,
to purchase 13.0 million shares of series A preferred stock, with an exercise price of $0.04 per
share, in connection with Toucan Capitals purchase of series A preferred stock on January 26,
2005. The number of shares issuable pursuant to the exercise of the warrant and the 24




---



##### Table of Contents



exercise price thereof is subject to adjustment in the event of stock splits, reverse stock splits, stock
dividends, dilutive events and the like.





Item 3. Defaults upon Senior Securities

None




Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of our stockholders during the three months ended March
31, 2005.




Item 5. Other Information

(a) Toucan Capital Loan

On May 13, 2005, we borrowed an additional $450,000 from Toucan Capital and issued
warrants to purchase up to 4.5 million additional shares of our capital stock. The warrant,
with a contractual life of 7 years, has an exercise price of $0.04 per share. The number of
shares issuable pursuant to the exercise of the warrant and the exercise price thereof is
subject to adjustment in the event of stock splits, reverse stock splits, stock dividends,
dilutive events and the like.




Item 6. Exhibits

a) Exhibits

3.1
    
    Sixth Amended and Restated
Certificate of Incorporation. (3.1) (1)3.2
    
    Certificate of Designations, Preferences and Rights of Series A Cumulative
Convertible Preferred Stock. (3.1) (2)3.3
    
    Second Amended and Restated Bylaws
of Northwest Biotherapeutics, Inc. (3.2) (2)10.1
    
    Securities Purchase Agreement between Northwest Biotherapeutics, Inc. and Toucan
Capital Fund II, LP dated January 26, 2005. (10.1) (2)10.2
    
    Warrant to purchase securities of the Company dated January 26, 2005 issued to
Toucan Capital Fund II, L.P. (10.2) (2) 25




---



##### Table of Contents



10.3
    
    Amendment No. 4 to the Amended and Restated Recapitalization Agreement between
Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P., dated January 26,
2005. (10.3) (2)10.4
    
    Second Amendment to the Amended and Restated Binding Term Sheet between Northwest
Biotherapeutics, Inc. and Toucan Capital Fund II, L.P., dated January 26, 2005.
(10.4) (2)10.5
    
    First Amendment to Warrants between Northwest Biotherapeutics, Inc. and Toucan
Capital Fund II, L.P. dated January 26, 2005. (10.5) (2)31.1
    
    Certification of President (Principal Executive Officer), Pursuant to Exchange Act Rules
13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2
    
    Certification of Controller (Principal Financial and Accounting Officer), Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.32.1
    
    Certification of President Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification of Controller Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   (1) Incorporated by reference to the exhibit shown in the preceding parenthese filed with the
Registrants Form DEF 14A on December 2, 2004. (2) Incorporated by reference to the exhibit shown in the preceding parenthese filed with the
Registrants Form 8-K on February 1, 2005. 26




---



##### Table of Contents



SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INCDated: May 13, 2005
    By:
    /s/ Alton L. BoyntonAlton L. BoyntonPresident (Principal
Executive Officer) Dated: May 13, 2005
    By:
    /s/ Larry L. RichardsLarry L. RichardsController
(Principal Financial and
Accounting Officer) 27




---



##### Table of Contents



NORTHWEST
BIOTHERAPEUTICS, INC.
(A Development Stage Company) 
 EXHIBIT INDEX ExhibitNumber
    
    Description3.1
    
    Sixth Amended and Restated
Certificate of Incorporation. (3.1) (1)3.2
    
    Certificate of Designations, Preferences and Rights of Series A Cumulative
Convertible Preferred Stock. (3.1) (2)3.3
    
    Second Amended and Restated Bylaws
of Northwest Biotherapeutics, Inc. (3.2) (2)10.1
    
    Securities Purchase Agreement between Northwest Biotherapeutics, Inc. and Toucan
Capital Fund II, LP dated January 26, 2005. (10.1) (2)10.2
    
    Warrant to purchase securities of the Company dated January 26, 2005 issued to
Toucan Capital Fund II, L.P. (10.2) (2)10.3
    
    Amendment No. 4 to the Amended and Restated Recapitalization Agreement between
Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P., dated January 26,
2005. (10.3) (2)10.4
    
    Second Amendment to the Amended and Restated Binding Term Sheet between Northwest
Biotherapeutics, Inc. and Toucan Capital Fund II, L.P., dated January 26, 2005.
(10.4) (2)10.5
    
    First Amendment to Warrants between Northwest Biotherapeutics, Inc. and Toucan
Capital Fund II, L.P. dated January 26, 2005. (10.5) (2)31.1
    
    Certification of President (Principal Executive Officer), Pursuant to Exchange Act Rules
13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2
    
    Certification of Controller (Principal Financial and Accounting Officer), Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.32.1
    
    Certification of President Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification of Controller Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   (1) Incorporated by reference to the exhibit shown in the preceding parenthese filed with the
Registrants Form DEF 14A on December 2, 2004. (2) Incorporated by reference to the exhibit shown in the preceding parenthese filed with the
Registrants Form 8-K on February 1, 2005. 28